18 unknown, 4 completed, 2 not yet recruiting, 1 active not recruiting. 24 Phase 2, 6 Phase 1, 4 Phase 3, 1 Phase 4.
Follow AL3818: new trials by email Literature Review of AL3818 trials Research Report on AL3818
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Catequentinib Hydrochloride (AL3818) in Endometrial, LGSOC, STS or GBM Cancers AL58805, AL3818, Temozolomide (TMZ) - Endometrial Neoplasms, Ovarian Neoplasms | Phase 1 / Phase 2 | Not yet recruiting | Advenchen Pharmaceuticals, LLC. | 138 | 2026-09-01 | 2026-09-10 |
| Benmelstobart Plus Anlotinib, Chemotherapy and Thoracic Radiation for Limited-Stage Small Cell Lung Cancer Benmelstobart, Anlotinib, Cisplatin or carboplatin - Limited-stage Small Cell Lung Cancer (LS-SCLC) | Phase 2 | Not yet recruiting | Yayi He | 27 | 2026-04-20 | 2026-04-20 |
| A Phase Ⅱ Study of Anlotinib Combined With Tislelizumab and AT in the Neoadjuvant Treatment of Triple-negative Breast Cancer AT regimen, Tislelizumab, Anlotinib - Triple-negative Breast Cancer | Phase 2 | Unknown | Sichuan Provincial People's Hospital | 32 | 2023-09-15 | 2024-01-22 |
| Cadonilimab in Patients (Pts) With Advanced Non-small Cell Lung Cancer (NSCLC) Cadonilimab, Anlotinib, Docetaxel - NSCLC Stage IV, NSCLC Stage IIIB | Phase 1 / Phase 2 | Unknown | Shanghai Chest Hospital | 50 | 2023-02-16 | 2024-06-17 |
| PD-1 Inhibitor and Anlotinib Combined With Multimodal Radiotherapy in Recurrent or Metastatic Anaplastic Thyroid Cancer Tislelizumab, Anlotinib, Radiotherapy - Thyroid Cancer | Phase 2 | Unknown | West China Hospital | 20 | 2022-12-30 | 2022-12-21 |
| Anlotinib and Radiotherapy in Resectable Soft Tissue Sarcoma Anlotinib, Radiotherapy, Surgery - Soft Tissue Sarcoma, High Risk of Recurrence | Phase 2 | Unknown | Ruijin Hospital | 41 | 2022-11-01 | 2022-11-02 |
| Anlotinib , Penpulimab Combined With SBRT for Metastatic Non-Small Cell Lung Cancer (NSCLC) Anlotinib Hydrochloride, penpulimab, SBRT - Non-Small Cell Lung Cancer | Phase 2 | Unknown | Peking University Third Hospital | 32 | 2022-09-12 | 2022-08-03 |
| Sintilimab Combined With Anlotinib Therapy for Initially Unresectable Non-small Cell Lung Cancer Sintilimab, Anlotinib - Carcinoma, Non-Small-Cell Lung | Phase 2 | Unknown | Peking Union Medical College Hospital | 93 | 2022-04-01 | 2022-04-01 |
| Anlotinib Combined With Platinum/Gemcitabine for First Line Treatment of Advanced Urothelial Carcinoma Anlotinib, Cisplatin, Carboplatin - Urothelial Carcinoma, Anlotinib | Phase 2 | Unknown | Tianjin Medical University Second Hospital | 53 | 2021-10-01 | 2021-09-01 |
| Toripalimab Combined With Anlotinib and SBRT in Patients With Untreated Brain Metastases of Driven Gene-negative NSCLC Toripalimab, Anlotinib, SBRT 7Gy✖️5 QD - NSCLC | Phase 1 | Completed | Hubei Cancer Hospital | 13 | 2021-10-01 | 2025-02-07 |
| The Efficacy and Safety of Anlotinib Combined With Fulvestrant in Patients With Advanced Breast Cancer anlotinib, fulvestrant - Breast Neoplasm Female | Phase 2 | Unknown | Zhejiang Cancer Hospital | 40 | 2021-09-01 | 2021-10-12 |
| Study of Pembrolizumab Combined With Anlotinib in the First Line Therapy for R/M HNSCC With CPS≥1 Pembrolizumab, Anlotinib - Head and Neck Squamous Cell Carcinoma | Phase 2 | Unknown | Shi Yuankai | 20 | 2021-07-18 | 2021-08-11 |
| Gefitinib With Anlotinib in Advanced Non-squamous NSCLC Patients With Uncleared Plasma ctDNA EGFRm After First-line Treatment With Gefitinib Gefitinib, Anlotinib - Non-small Cell Lung Cancer, EGFR Gene Mutation | Phase 2 | Unknown | Second Affiliated Hospital of Nanchang University | 240 | 2020-05-01 | 2020-04-24 |
| Anlotinib in Combination With PD1 With Gemcitabine Plus(+)Cisplatin for Unresectable or Metastatic Biliary Tract Cancer Anlotinib Hydrochloride in Combination With PD1 With Gemcitabine Plus(+)Cisplatin, Gemcitabine Plus(+)Cisplatin - Biliary Tract Cancer | Phase 2 | Unknown | Zhejiang Cancer Hospital | 80 | 2020-01-01 | 2020-03-09 |
| Hypofractionated Stereotactic Radiotherapy With Anlotinib in Patients With Recurrent High-Grade Gliomas Hypofractionated Stereotactic Radiotherapy, Anlotinib - Malignant Glioma | Phase 2 | Unknown | Huashan Hospital | 22 | 2019-12-16 | 2024-01-05 |
| A Study of Neoadjuvant Chemotherapy Plus Anlotinib in Stage III(N2) Non-small-cell Lung Cancer Anlotinib hydrochloride, platinum-based chemotherapy medicine - Stage III Non-small-cell Lung Cancer | Phase 2 | Unknown | The First Affiliated Hospital of Guangzhou Medical University | 50 | 2019-12-01 | 2019-11-29 |
| Evaluation of AL3818 in Combination With Nivolumab in Solid Tumors AL3818, Nivolumab Injection - Solid Tumor, Adult, Soft Tissue Sarcoma | Phase 1 / Phase 2 | Active not recruiting | Sarcoma Oncology Research Center, LLC | 56 | 2019-10-17 | 2025-02-24 |
| Anlotinib After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer（ALTER-L029） Anlotinib - Non-Small Cell Lung Cancer Stage III | Phase 2 | Completed | Anhui Shi, MD | 90 | 2019-04-12 | 2023-06-12 |
| A Study of Lobaplatin/Etoposide With or Without Anlotinib Maintenance Therapy in Patients With ES-SCLC Anlotinib Hydrochloride, Lobaplatin, Etoposide - Small Cell Lung Carcinoma | Phase 2 | Unknown | The First Affiliated Hospital of Guangzhou Medical University | 60 | 2019-03-01 | 2019-11-29 |
| Anlotinib Hydrochloride For Advanced Soft Tissue Sarcoma Patients Who Do Not Receive Chemotherapy Anlotinib - Soft Tissue Sarcoma | Phase 2 | Unknown | Second Affiliated Hospital, Zhejiang University, School of Medicine | 44 | 2019-01-01 | 2019-01-03 |
Showing 20 of 29. Sign in to see all of them.
Carcinoma, Non-Small-Cell Lung (8) · Sarcoma (6) · Endometrial Neoplasms (3) · Ovarian Neoplasms (3) · Small Cell Lung Carcinoma (3) · Uterine Cervical Neoplasms (2) · Biliary Tract Neoplasms (1) · Brain Neoplasms (1) · Carcinoma, Hepatocellular (1) · Carcinoma, Transitional Cell (1) · Colorectal Neoplasms (1) · Fallopian Tube Neoplasms (1) · Glioblastoma (1) · Glioma (1) · Head and Neck Neoplasms (1)
Advenchen Laboratories, LLC (4) · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (2) · The First Affiliated Hospital of Guangzhou Medical University (2) · Zhejiang Cancer Hospital (2) · Advenchen Pharmaceuticals, LLC. (1) · Anhui Shi, MD (1) · First Affiliated Hospital Xi'an Jiaotong University (1) · Huashan Hospital (1) · Hubei Cancer Hospital (1) · Peking Union Medical College Hospital (1) · Peking University People's Hospital (1) · Peking University Third Hospital (1) · Ruijin Hospital (1) · Sarcoma Oncology Research Center, LLC (1) · Second Affiliated Hospital of Nanchang University (1)
China (22) · United States (5) · Italy (2) · Spain (2) · United Kingdom (2) · South Korea (1)
Baohui Han, M.D (1) · Baohui Han, professor (1) · Carlos K Matsuoka, MD (1) · Chunmei Bai, Professor (1) · Enmin Wang, MD (1) · Hui-Chuan Sun, MD&PhD (1) · Jia Fan, MD&PhD (1) · Jian Huang (1) · Jianqiang Cai, doctor (1) · Jianya Zhou, M.D (1) · Jieer Ying (1) · Jiexia Zhang (1) · Jiexia Zhang, prof. (1) · Jing Luo, Prof. (1)
PMID 10999768, PMID 18577994, PMID 19692680, PMID 19692684, PMID 20022809, PMID 20966921, PMID 23594426, PMID 24312144, PMID 25829397, PMID 25907450, PMID 28212993, PMID 28958502, PMID 30017884, PMID 30032842, PMID 30098152, PMID 30207593, PMID 30392239, PMID 30783814, PMID 31411950, PMID 31439584, PMID 31689797, PMID 31751012, PMID 32077550, PMID 32944404, PMID 34941047, PMID 35448002, PMID 37185961, PMID 38718190, PMID 40593475